Toxic epidermal necrolysis: Review of pathogenesis and management

French, 2006, Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding, Allergol Int, 55, 9, 10.2332/allergolint.55.9 Pereira, 2007, Toxic epidermal necrolysis, J Am Acad Dermatol, 56, 181, 10.1016/j.jaad.2006.04.048 Wolff, 2007 Rzany, 1993, Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany, Arch Dermatol, 129, 1059, 10.1001/archderm.1993.01680290135026 Wu, 2003, A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients, J Immunol, 170, 132, 10.4049/jimmunol.170.1.132 Quinn, 2005, Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis, Arch Dermatol, 141, 683, 10.1001/archderm.141.6.683 Paquet, 2007, Toxic epidermal necrolysis: revisiting the tentative link between early apoptosis and late necrosis (review), Int J Mol Med, 19, 3 Roujeau, 1994, Severe adverse cutaneous reactions to drugs, N Engl J Med, 331, 1272, 10.1056/NEJM199411103311906 Letkko, 2005, Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature, Ann Allergy Asthma Immunol, 94, 419, 10.1016/S1081-1206(10)61112-X Imahara, 2006, SCORTEN overestimates mortality in the setting of a standardized treatment protocol, J Burn Care Res, 27, 270, 10.1097/01.BCR.0000216532.71360.9B Mukasa, 2008, Management of toxic epidermal necrolysis and related syndromes, Postgrad Med J, 84, 60, 10.1136/pgmj.2007.061465 Bastuji-Garin, 2000, SCORTEN: a severity-of-illness score for toxic epidermal necrolysis, J Invest Dermatol, 115, 149, 10.1046/j.1523-1747.2000.00061.x Mockenhaupt, 2008, Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study, J Invest Dermatol, 128, 35, 10.1038/sj.jid.5701033 Dobrosavljevic, 1999, Toxic epidermal necrolysis following morbilli-parotitis vaccination, J Eur Acad Dermatol Venereol, 13, 59, 10.1111/j.1468-3083.1999.tb00846.x Stevens, 1978, Mycoplasma pneumoniae infections in children, Arch Dis Child, 53, 38, 10.1136/adc.53.1.38 Chung, 2004, Medical genetics: a marker for Stevens-Johnson syndrome, Nature, 428, 486, 10.1038/428486a Hung, 2005, HLA-B∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol, Proc Natl Acad Sci U S A, 102, 4134, 10.1073/pnas.0409500102 Locharernkul, 2008, Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B∗1502 allele in Thai population, Epilepsia, 49, 2087, 10.1111/j.1528-1167.2008.01719.x Man, 2007, Association between HLA-B∗1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese, Epilepsia, 48, 1015, 10.1111/j.1528-1167.2007.01022.x Information for Healthcare Professionals: Dangerous or Even Fatal Skin Reactions - Carbamazepine. United States Food and Drug Administration. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718.htm. Accessed November 16, 2011. Wu, 2006, Activation of T cells by carbamazepine and carbamazepine metabolites, J Allergy Clin Immunol, 118, 233, 10.1016/j.jaci.2006.03.005 Kaniwa, 2008, HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis, Pharmacogenomics, 9, 1617, 10.2217/14622416.9.11.1617 Lonjou, 2008, A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs, Pharmacogenet Genomics, 18, 99, 10.1097/FPC.0b013e3282f3ef9c Tassaneeyakul, 2009, Strong association between HLA-B∗5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population, Pharmacogenet Genomics, 19, 704, 10.1097/FPC.0b013e328330a3b8 Abe, 2008, Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases, J Dermatol Sci, 52, 151, 10.1016/j.jdermsci.2008.06.003 Viard, 1998, Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin, Science, 282, 490, 10.1126/science.282.5388.490 Abe, 2003, Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand, Am J Pathol, 162, 1515, 10.1016/S0002-9440(10)64284-8 Stur, 2007, Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas, J Invest Dermatol, 127, 802, 10.1038/sj.jid.5700648 Tohyama, 2009, The influence of hepatic damage on serum soluble Fas ligand levels of patients with drug rashes, J Allergy Clin Immunol, 123, 971, 10.1016/j.jaci.2009.01.064 Tohyama, 2008, A marked increase in serum soluble Fas ligand in drug-induced hypersensitivity syndrome, Br J Dermatol, 159, 981, 10.1111/j.1365-2133.2008.08750.x Chung, 2008, Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis, Nat Med, 14, 1343, 10.1038/nm.1884 Deng, 2005, Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator, J Immunol, 174, 5243, 10.4049/jimmunol.174.9.5243 Paquet, 2010, New insights in toxic epidermal necrolysis (Lyell’s syndrome): clinical considerations, pathobiology and targeted treatments revisited, Drug Saf, 33, 189, 10.2165/11532540-000000000-00000 Paquet, 2007, Glutathione-S-transferase pi expression in toxic epidermal necrolysis: a marker of putative oxidative stress in keratinocytes, Skin Pharmacol Physiol, 20, 66, 10.1159/000097652 Hayes, 1995, The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance, Crit Rev Biochem Mol Biol, 30, 445, 10.3109/10409239509083491 Hermes, 1996, [Plasmapheresis and immunopathogenetic aspects of toxic epidermal necrolysis], Hautarzt, 47, 749, 10.1007/s001050050502 Paquet, 1994, Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis, Arch Dermatol, 130, 605, 10.1001/archderm.1994.01690050073012 Posadas, 2002, Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity, J Allergy Clin Immunol, 109, 155, 10.1067/mai.2002.120563 Posadas, 2002, Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs, Blood Cells Mol Dis, 29, 179, 10.1006/bcmd.2002.0555 Arnold, 1999, Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: modulation by cytokines, J Immunol, 162, 7140, 10.4049/jimmunol.162.12.7140 Chave, 2005, Toxic epidermal necrolysis: current evidence, practical management and future directions, Br J Dermatol, 153, 241, 10.1111/j.1365-2133.2005.06721.x Moncada, 1991, Nitric oxide: physiology, pathophysiology, and pharmacology, Pharmacol Rev, 43, 109 Kroncke, 1997, Nitric oxide: cytotoxicity versus cytoprotection—how, why, when, and where?, Nitric Oxide, 1, 107, 10.1006/niox.1997.0118 Morel, 2010, CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis, J Allergy Clin Immunol, 125, 703, 10.1016/j.jaci.2009.10.030 Nassif, 2004, Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells, J Allergy Clin Immunol, 114, 1209, 10.1016/j.jaci.2004.07.047 Mizukawa, 2008, In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption, Br J Dermatol, 158, 1230, 10.1111/j.1365-2133.2008.08516.x Takahashi, 2009, Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome, J Immunol, 182, 8071, 10.4049/jimmunol.0804002 Bellon, 2010, Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases, Br J Dermatol, 162, 1014, 10.1111/j.1365-2133.2009.09627.x de Araujo, 2011, Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis, Exp Dermatol, 20, 107, 10.1111/j.1600-0625.2010.01176.x Verneuil, 2009, Endothelial cell apoptosis in severe drug-induced bullous eruptions, Br J Dermatol, 161, 1371, 10.1111/j.1365-2133.2009.09357.x Garcia-Doval, 2000, Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?, Arch Dermatol, 136, 323, 10.1001/archderm.136.3.323 McGee, 1998, Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center, Plast Reconstr Surg, 102, 1018, 10.1097/00006534-199809040-00014 Palmieri, 2002, A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century, J Burn Care Rehabil, 23, 87, 10.1097/00004630-200203000-00004 Endorf, 2008, Toxic epidermal necrolysis clinical guidelines, J Burn Care Res, 29, 706, 10.1097/BCR.0b013e3181848bb1 Boorboor, 2008, Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients, Burns, 34, 487, 10.1016/j.burns.2007.06.008 Dorafshar, 2008, Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach, Plast Reconstr Surg, 122, 154, 10.1097/PRS.0b013e3181773d5d Huang, 2008, AQUACEL Ag in the treatment of toxic epidermal necrolysis (TEN), Burns, 34, 63, 10.1016/j.burns.2006.12.008 Revuz, 1987, Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients, Arch Dermatol, 123, 1160, 10.1001/archderm.1987.01660330071012 Halebian, 1986, Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids, Ann Surg, 204, 503, 10.1097/00000658-198611000-00001 Heimbach, 1987, Toxic epidermal necrolysis. A step forward in treatment, JAMA, 257, 2171, 10.1001/jama.1987.03390160057026 Schneck, 2008, Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study, J Am Acad Dermatol, 58, 33, 10.1016/j.jaad.2007.08.039 Herndon, 1995, Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids, J Am Coll Surg, 180, 340 Al-Mutairi, 2004, Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis, Int J Dermatol, 43, 847, 10.1111/j.1365-4632.2004.02048.x Campione, 2003, High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis, Acta Derm Venereol, 83, 430 Prins, 2003, Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study, Dermatology, 207, 96, 10.1159/000070957 Shortt, 2004, Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis, J Burn Care Rehabil, 25, 246, 10.1097/01.BCR.0000124746.33279.86 Stella, 2001, Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience, Dermatology, 203, 45, 10.1159/000051702 Trent, 2003, Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience, Arch Dermatol, 139, 39, 10.1001/archderm.139.1.39 Tristani-Firouzi, 2002, Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children, J Am Acad Dermatol, 47, 548, 10.1067/mjd.2002.127249 Brown, 2004, Toxic epidermal necrolysis: does immunoglobulin make a difference?, J Burn Care Rehabil, 25, 81, 10.1097/01.BCR.0000105096.93526.27 Bachot, 2003, Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression, Arch Dermatol, 139, 33, 10.1001/archderm.139.1.33 French, 2006, Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding, Int Immunopharmacol, 6, 543, 10.1016/j.intimp.2005.11.012 Trent, 2006, Toxic epidermal necrolysis and intravenous immunoglobulin: a review, Semin Cutan Med Surg, 25, 91, 10.1016/j.sder.2006.04.004 Bamichas, 2002, Plasma exchange in patients with toxic epidermal necrolysis, Ther Apher, 6, 225, 10.1046/j.1526-0968.2002.00409.x Chaidemenos, 1997, Plasmapheresis in toxic epidermal necrolysis, Int J Dermatol, 36, 218, 10.1046/j.1365-4362.1997.00192.x Egan, 1999, Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis, J Am Acad Dermatol, 40, 458, 10.1016/S0190-9622(99)70497-4 Kamanabroo, 1985, Plasmapheresis in severe drug-induced toxic epidermal necrolysis, Arch Dermatol, 121, 1548, 10.1001/archderm.1985.01660120074023 Sakellariou, 1991, Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN), Int J Artif Organs, 14, 634, 10.1177/039139889101401006 Arevalo, 2000, Treatment of toxic epidermal necrolysis with cyclosporin A, J Trauma, 48, 473, 10.1097/00005373-200003000-00017 Fischer, 2002, Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis, Br J Dermatol, 146, 707, 10.1046/j.1365-2133.2002.46833.x Frangogiannis, 1996, Cyclophosphamide in the treatment of toxic epidermal necrolysis, South Med J, 89, 1001, 10.1097/00007611-199610000-00015 Wolkenstein, 1998, Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis, Lancet, 352, 1586, 10.1016/S0140-6736(98)02197-7 Redondo, 1997, Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine, Br J Dermatol, 136, 645, 10.1111/j.1365-2133.1997.tb02175.x Velez, 2002, Toxic epidermal necrolysis treated with N-acetylcysteine, J Am Acad Dermatol, 46, 469, 10.1067/mjd.2002.118557